FDA Feedback on Xanamem Alzheimers Trail
Filed with ASX · · 1 page · English
Actinogen Medical Limited on 6ix
Story so far
Earlier from Actinogen Medical
- R&D Tax Rebate
- New Patents Allowed for B-HSD1 Inhibitor
- Further results in bio-ethanol test program
- Announcement of non-renounceable rights issue
- Appendix 4C & Commentary
Later from Actinogen Medical
- Significant Advance in Development of Alzheimers Drug
- FDA Approval to Commence Alzheimers Disease Clinical Trial
- Appendix 4C - quarterly
- Xanamem Research Published in Prestigious Medical Journal
- UK Regulatory Approval for Alzheimers Clinical Trial-XanADu
Follow Actinogen Medical into a list and get an email when it puts out news.
Follow Actinogen Medical